ストックスクリーナーアプリを入手
11.87
3.58%
-0.43
アフターアワーズ：
11.87
前日終値:
$12.30
開ける：
$12.3
24時間の取引高:
903.07K
Relative Volume:
0.39
時価総額：
$2.07B
収益：
$61.10M
当期純損益:
$-138.36M
株価収益率:
-8.7926
EPS:
-1.35
ネットキャッシュフロー:
$-90.59M
1週間 パフォーマンス:
-3.66%
1か月 パフォーマンス:
-2.87%
6か月 パフォーマンス:
+75.18%
1年 パフォーマンス:
+30.19%
1日の値動き範囲:
$11.84
$12.36
1週間の範囲:
$11.68
$12.49
52週間の値動き範囲:
$5.80
$12.91
Ocular Therapeutix Inc Stock (OCUL) Company Profile
OCUL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
11.87 | 2.14B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-08 | 開始されました | William Blair | Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-11 | 開始されました | Needham | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-20 | アップグレード | TD Cowen | Hold → Buy |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-02-09 | 開始されました | BofA Securities | Buy |
| 2023-04-21 | 開始されました | Robert W. Baird | Outperform |
| 2022-08-10 | 再開されました | Berenberg | Buy |
| 2021-08-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-11-13 | 繰り返されました | Raymond James | Strong Buy |
| 2020-08-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-03 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | ダウングレード | Cowen | Outperform → Market Perform |
| 2019-05-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-05-21 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 開始されました | Raymond James | Strong Buy |
| 2018-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-07-12 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-06-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-08-11 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-02-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Ocular Therapeutix Inc (OCUL) 最新ニュース
Ocular Therapeutix Inc. Shows Support at Fibonacci LevelJuly 2025 Outlook & Weekly High Conviction Ideas - newsyoung.net
Ocular Therapeutix Inc. Stock Poised for Technical ComebackJuly 2025 Closing Moves & Weekly Top Stock Performers List - mustnews.co.kr
Ocular gets FDA agreement for registrational trial of Axpaxl - MSN
Quant Strategy Flags Ocular Therapeutix Inc. for EntryJuly 2025 Earnings & Community Consensus Picks - newsyoung.net
Ocular Therapeutix receives FDA agreement under SPA for registrational trial of AXPAXLI in NPDR - Eyes On Eyecare
Ocular Therapeutix at H.C. Wainwright: Strategic Moves in Eye Care By Investing.com - Investing.com Canada
Ocular Therapeutix receives FDA agreement under special protocol assessment for registrational trial of AXPAXLI - Ophthalmology Times
Ocular Therapeutix™ Receives FDA Agreement Under Special - GlobeNewswire
Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating - TipRanks
Ocular Therapeutix's AXPAXLI: A Game-Changer in Diabetic Retinopathy and Wet AMD Markets - AInvest
Ocular Therapeutix Receives FDA Agreement for Axpaxl Trial in NPDR Treatment - AInvest
Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial By Investing.com - Investing.com Australia
Ocular Therapeutix secures FDA agreement for diabetic retinopathy trial - Investing.com
Ocular Therapeutix Receives FDA Agreement on AXPAXLI Registrational Trial Design. - AInvest
Ocular Therapeutix Receives FDA Approval for Registrational Trial of AXPAXLI in NPDR, Plans to Outline Clinical Trial Design at Investor Day - AInvest
Revolutionary Once-Yearly Eye Treatment Gets FDA Trial Approval: Could Help 9M Diabetic Retinopathy Patients - Stock Titan
Weaker Q2 Results and Rising Losses Might Change the Case for Investing in Ocular Therapeutix (OCUL) - simplywall.st
ETF Channel: ITOT Expected to Reach $154 - AInvest
Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter Report - Yahoo Finance
Optimistic Buy Rating for Ocular Therapeutix Driven by Promising Clinical Trials and Strategic Decisions - TipRanks
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN
RBC Capital Maintains Buy Rating on Ocular Therapeutix with $17 Price Target - AInvest
Ocular Therapeutix stock hits 52-week high at 12.38 USD By Investing.com - Investing.com Nigeria
Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com
Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune
Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com
Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix Q2 2025 Sales Down 18%, R&D Expenses Surge 76.9% Amid Reimbursement Pressure - AInvest
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks
OCUL Sales Drop 18% - The Motley Fool
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest
Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada
Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target By Investing.com - Investing.com South Africa
Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com Canada
Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops - Investing.com
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocular Therapeutix tumbles as Q2 results miss estimates By Investing.com - Investing.com South Africa
Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com India
Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest
Ocular Therapeutix Inc (OCUL) 財務データ
収益
当期純利益
現金流量
EPS
1.34%
0.52%
大文字化:
|
ボリューム (24 時間):